S179D-Human PRL, a Pseudophosphorylated Human PRL Analog, Is an Agonist and Not an Antagonist.
暂无分享,去创建一个
J. Martial | P. Kelly | S. Jeay | D. Madern | M. Llovera | V. Goffin | S. Kinet | S. Bernichtein
[1] C. Chen,et al. Administration of unmodified prolactin (U-PRL) and a molecular mimic of phosphorylated prolactin (PP-PRL) during rat pregnancy provides evidence that the U-PRL:PP-PRL ratio is crucial to the normal development of pup tissues. , 2001, The Journal of endocrinology.
[2] E. Byrnes,et al. Central infusions of the recombinant human prolactin receptor antagonist, S179D-PRL, delay the onset of maternal behavior in steroid-primed, nulliparous female rats. , 2001, Endocrinology.
[3] A. Walker,et al. Effects of prolactin on osteoblast alkaline phosphatase and bone formation in the developing rat. , 2000, American journal of physiology. Endocrinology and metabolism.
[4] P. Kelly,et al. Human prolactin (hPRL) antagonists inhibit hPRL-activated signaling pathways involved in breast cancer cell proliferation , 2000, Oncogene.
[5] P. Ingleton,et al. Dissociation of Janus Kinase 2 and Signal Transducer and Activator of Transcription 5 Activation after Treatment of Nb2 Cells with a Molecular Mimic of Phosphorylated Prolactin1. , 1999, Endocrinology.
[6] J. Martial,et al. Biological Properties of Human Prolactin Analogs Depend Not Only on Global Hormone Affinity, but Also on the Relative Affinities of Both Receptor Binding Sites* , 1999, The Journal of Biological Chemistry.
[7] P. Kelly,et al. The Human Growth Hormone Antagonist B2036 Does Not Interact with the Prolactin Receptor. , 1999, Endocrinology.
[8] R. Baron,et al. Osteoblasts Are a New Target for Prolactin : Analysis of Bone Formation in Prolactin Receptor Knockout Mice * , 1998 .
[9] P. Kelly,et al. Should prolactin be reconsidered as a therapeutic target in human breast cancer? , 1999, Molecular and Cellular Endocrinology.
[10] P. Ingleton,et al. Dissociation of Janus kinase 2 and signal transducer and activator of transcription 5 activation after treatment of Nb2 cells with a molecular mimic of phosphorylated prolactin. , 1999, Endocrinology.
[11] P. Kelly,et al. Prolactin (PRL) and its receptor: actions, signal transduction pathways and phenotypes observed in PRL receptor knockout mice. , 1998, Endocrine reviews.
[12] A. Walker,et al. Development of recombinant human prolactin receptor antagonists by molecular mimicry of the phosphorylated hormone. , 1998, Endocrinology.
[13] N. Horseman,et al. Defective mammopoiesis, but normal hematopoiesis, in mice with a targeted disruption of the prolactin gene , 1997, The EMBO journal.
[14] G. Elberg,et al. Direct evidence that lactogenic hormones induce homodimerization of membrane‐anchored prolactin receptor in intact Nb2‐11C rat lymphoma cells , 1997, FEBS letters.
[15] P. Kelly,et al. Null mutation of the prolactin receptor gene produces multiple reproductive defects in the mouse. , 1997, Genes & development.
[16] P. Kelly,et al. Prolactin and growth hormone receptors , 1996, Clinical endocrinology.
[17] J. Martial,et al. Sequence-function relationships within the expanding family of prolactin, growth hormone, placental lactogen, and related proteins in mammals. , 1996, Endocrine reviews.
[18] J. Martial,et al. Antagonistic Properties of Human Prolactin Analogs That Show Paradoxical Agonistic Activity in the Nb2 Bioassay* , 1996, The Journal of Biological Chemistry.
[19] J. Martial,et al. Characterization of Lactogen Receptor-binding Site 1 of Human Prolactin* , 1996, The Journal of Biological Chemistry.
[20] A. Walker,et al. Identification of the Major Site of Rat Prolactin Phosphorylation as Serine 177 (*) , 1996, The Journal of Biological Chemistry.
[21] J A Wells,et al. Binding in the growth hormone receptor complex. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[22] J. Martial,et al. Use of a model to understand prolactin and growth hormone specificities. , 1995, Protein engineering.
[23] P. Kelly,et al. Functional activity of the human prolactin receptor and its ligands , 1995, Molecular and Cellular Endocrinology.
[24] C. Brooks,et al. Biological activity of phosphorylated and dephosphorylated bovine prolactin , 1995, Molecular and Cellular Endocrinology.
[25] G. Fuh,et al. Prolactin Receptor Antagonists That Inhibit the Growth of Breast Cancer Cell Lines (*) , 1995, The Journal of Biological Chemistry.
[26] Y. Sinha. Structural variants of prolactin: occurrence and physiological significance. , 1995, Endocrine reviews.
[27] M. Dattani,et al. G120R, a Human Growth Hormone Antagonist, Shows Zinc-dependent Agonist and Antagonist Activity on Nb2 Cells (*) , 1995, The Journal of Biological Chemistry.
[28] P. Dannies,et al. Lack of correlation of distribution of prolactin (PRL) charge isoforms with induction of PRL storage. , 1995, Endocrinology.
[29] J. Martial,et al. Evidence for a second receptor binding site on human prolactin. , 1994, The Journal of biological chemistry.
[30] H. Rui,et al. JAK2 activation and cell proliferation induced by antibody-mediated prolactin receptor dimerization. , 1994, Endocrinology.
[31] B. Groner,et al. Prolactin induces phosphorylation of Tyr694 of Stat5 (MGF), a prerequisite for DNA binding and induction of transcription. , 1994, The EMBO journal.
[32] P. De Meyts,et al. Receptor dimerization determines the effects of growth hormone in primary rat adipocytes and cultured human IM-9 lymphocytes. , 1994, Endocrinology.
[33] A. Ullrich,et al. Prolactin-induced proliferation of Nb2 cells involves tyrosine phosphorylation of the prolactin receptor and its associated tyrosine kinase JAK2. , 1994, The Journal of biological chemistry.
[34] B. Groner,et al. Mammary gland factor (MGF) is a novel member of the cytokine regulated transcription factor gene family and confers the prolactin response. , 1994, The EMBO journal.
[35] C. Brooks,et al. Isolation and characterization of phosphorylated bovine prolactin. , 1993, The Biochemical journal.
[36] A. Walker,et al. Dephosphorylation of standard prolactin produces a more biologically active molecule: evidence for antagonism between nonphosphorylated and phosphorylated prolactin in the stimulation of Nb2 cell proliferation. , 1993, Endocrinology.
[37] J. Martial,et al. The addition of nine residues at the C-terminus of human prolactin drastically alters its biological properties. , 1993, European journal of biochemistry.
[38] M. A. Andrade,et al. Evaluation of secondary structure of proteins from UV circular dichroism spectra using an unsupervised learning neural network. , 1993, Protein engineering.
[39] W. Wood,et al. Mechanism-based design of prolactin receptor antagonists. , 1993, The Journal of biological chemistry.
[40] J. Martial,et al. Alanine-scanning mutagenesis of human prolactin: importance of the 58-74 region for bioactivity. , 1992, Molecular endocrinology.
[41] D. Goeddel,et al. Rational design of potent antagonists to the human growth hormone receptor. , 1992, Science.
[42] L. Berghman,et al. Phosphorylation of prolactin and growth hormone. , 1992, Journal of molecular endocrinology.
[43] Y. Sinha. Prolactin variants , 1992, Trends in Endocrinology & Metabolism.
[44] P. Kelly,et al. The prolactin/growth hormone receptor family. , 1991, Endocrine reviews.
[45] F. Rentier-Delrue,et al. Bacterial production and purification of recombinant human prolactin , 1990, Biotechnology and applied biochemistry.
[46] G. Elberg,et al. Site-directed mutations of human growth hormone that selectively modify its lactogenic activity and binding properties. , 1990, Molecular endocrinology.
[47] C. Brooks,et al. Phosphorylated variant of bovine prolactin , 1990, Molecular and Cellular Endocrinology.
[48] M. Smith,et al. Bioactive recombinant methionyl bovine prolactin: structure-function studies using site-specific mutagenesis. , 1989, Molecular endocrinology.
[49] W. Oetting,et al. Phosphorylation of prolactin. , 1986, The Journal of biological chemistry.
[50] H. Aviv,et al. Inhibition of lactogenic activities of ovine prolactin and human growth hormone (hGH) by a novel form of a modified recombinant hGH. , 1986, Endocrinology.
[51] R. Noble,et al. Receptor-mediated mitogenic action of prolactin in a rat lymphoma cell line. , 1983, Endocrinology.
[52] D Coit,et al. Human prolactin. cDNA structural analysis and evolutionary comparisons. , 1981, The Journal of biological chemistry.
[53] R. Noble,et al. A new sensitive and specific bioassay for lactogenic hormones: measurement of prolactin and growth hormone in human serum. , 1980, The Journal of clinical endocrinology and metabolism.
[54] R. Noble,et al. Prolactin-stimulated growth of cell cultures established from malignant Nb rat lymphomas. , 1980, Cancer research.
[55] U. K. Laemmli,et al. Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4 , 1970, Nature.